ICER Report Concludes Comparative Value of PARP Inhibitors is Lacking

ICER Report Concludes Comparative Value of PARP Inhibitors is Lacking
The Institute for Clinical and Economic Review (ICER), an independent body that assesses the value of drugs newly approved by the U.S. Food and Drug Administration, confirmed that evidence is lacking for comparisons of outcomes using poly-ADP ribose polymerase (PARP) inhibitors to treat women with ovarian cancer. At the same time, ICER recommended lowering prices

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *